Global Antibody Conjugates Drugs Market 2016-2020

Global Antibody Conjugates Drugs Market 2016-2020

Category : Pharmaceuticals
Sub Category : Prescription Drugs
Published On : March  2016
Pages : 75

------------ Or -------------
About Antibody Drug Conjugates

ADCs, empowered monoclonal antibodies (mAbs), use chemical linkers with labile bonds to attach biologically active substances. ADCs target mAbs with the cancer killing ability of cytotoxic drugs, allowing sensitive discernment between healthy and diseased tissue.
Antibodies are the proteins produced by B-cells (from bone marrow) in the immune system. These proteins attach to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies that attach to different sites of an antigen. mAbs, complex proteins with high molecular weight, are monospecific as they are the clones of a single parent cell. They are of three types, chimeric, humanized, and fully human, and are often used for therapeutic and diagnostic purposes.

Technavios analysts forecast the global ADCs market to grow at a CAGR of 41.58% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global ADCs market for the period 2015-2020. To calculate the market size, the report considers revenue generated from the sales of ADCs used to treat cancer.

The market is divided into the following segments based on geography: 
• Americas

Technavio's report, Global Antibody Drug Conjugates Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market. 

Key vendors 
• F. Hoffmann-La Roche AG
• Seattle Genetics Inc.
• Takeda Pharmaceutical Company 

Other prominent vendors 
• AbbVie
• AbGenomics
• ADC Therapeutics
• Agensys
• ALMAC Group
• Ambrx
• Astellas Pharma
• AstraZeneca
• Bayer HealthCare
• Celldex Therapeutics
• Daiichi Sankyo
• Endo Pharmaceuticals
• Esperance Pharmaceuticals
• Formation Biologics
• Genmab
• GlaxoSmithKline
• Immunogen
• Kairos Therapeutics
• MedImmune
• Mersana Therapeutics
• Novartis
• Oxford Biotherapeutics
• Pfizer
• Stemcentrx
• Synthon Biopharmaceuticals
• Zymeworks

Market driver 
• Robust late-stage pipeline
• For a full, detailed list, view our report 

Market challenge 
• High developmental costs
• For a full, detailed list, view our report 

Market trend 
• Strategic alliances
• For a full, detailed list, view our report 

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors? 

You can request one free hour of our analysts time when you purchase this market report. Details are provided within the report.
PART 01: Executive summary
PART 02: Scope of the report
Market overview
Top-vendor offerings
PART 03: Market research methodology
Research methodology
Economic indicators
PART 04: Introduction
Key market highlights
PART 05: Overview of ADCs
Evolution of mAb therapeutics
Conjugated mAbs
Key components in ADCs
Next-generation ADCs
Outsourcing of ADCs manufacturing
Emergence of ADCs
Current marketed ADCs
PART 06: Pipeline portfolio
Information on pipeline candidates
PART 07: Market landscape
Market overview
Market size and forecast
Five forces analysis
PART 08: Market segmentation by MOA
IgG1 antibodies
HER2 antibodies
PART 09: Market segmentation by technologies used in ADCs
Seattle Genetics (SGEN) technology
ImmunoGen (IMGN) technology
Immunomedics (IMMU) technology
PART 10: Geographical segmentation
PART 11: Market drivers
Robust late-stage pipeline
Rising prevalence of cancers
Increase in demand for antibody conjugates
Reimbursement policies
PART 12: Impact of drivers
PART 13: Market challenges
High developmental costs
Stringent regulations
Risk of side effects
PART 14: Impact of drivers and challenges
PART 15: Market trends
Strategic alliances
Increased outsourcing of drug development
Emergence of targeted and combination therapies
PART 16: Vendor landscape
Competitive scenario
Key news
F. Hoffmann-La Roche
Seattle Genetics
Takeda Pharmaceuticals
PART 17: Appendix
List of abbreviations
PART 18: Explore Technavio

List of Exhibits
Exhibit 01: Product offerings
Exhibit 02: Comparison of small molecule and mAbs
Exhibit 03: Preparation of mAbs
Exhibit 04: Timeline of ADCs
Exhibit 05: Key components
Exhibit 06: Components of next-generation ADCs
Exhibit 07: Advantages of ADCs
Exhibit 08: Emergence of ADCs
Exhibit 09: Marked ADCs products
Exhibit 10: Pipeline portfolio of ADCs
Exhibit 11: Pipeline share of ADCs
Exhibit 12: Market share of ADCs in clinical development
Exhibit 13: Few target antigens for ADCs in clinical development
Exhibit 14: Top five companies share in ADC pipeline
Exhibit 15: Global ADCs market 2015-2020 ($ billions)
Exhibit 16: Five forces analysis
Exhibit 17: Global ADCs market segmentation by MOA
Exhibit 18: Components in IMGN technology
Exhibit 19: Share of ADCs technologies
Exhibit 20: Global ADCs market by geography 2015
Exhibit 21: ADCs market in Americas 2015
Exhibit 22: ADCs market in Europe 2015
Exhibit 23: ADCs market in Japan 2015
Exhibit 24: Global incidence of cancer 2015 and 2020
Exhibit 25: Impact of drivers
Exhibit 26: Impact of drivers and challenges
Exhibit 27: F. Hoffmann-La Roche: Pharmaceutical division segmentation by revenue 2015
Exhibit 28: F. Hoffmann-La Roche: ADC segmentation by revenue 2015
Exhibit 29: F. Hoffmann-La Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
Exhibit 30: F. Hoffmann-La Roche: Geographical segmentation of Kadcyla by revenue 2015
Exhibit 31: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in US 2013-2015 ($ millions)
Exhibit 32: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Europe 2014 and 2015 ($ millions)
Exhibit 33: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in Japan 2014-2015 ($ millions)
Exhibit 34: F. Hoffmann-La Roche: YoY revenue and growth rate of Kadcyla in ROW 2013-2015 ($ millions)
Exhibit 35: F. Hoffmann La-Roche: Kadcyla pipeline products
Exhibit 36: F. Hoffmann La-Roche: Key takeaways
Exhibit 37: Seattle Genetics: YoY revenue and growth rate of ADCETRIS in US and Canada ($ millions)
Exhibit 38: Seattle Genetics: ADCETRIS developmental pipeline
Exhibit 39: Seattle Genetics: ADCs pipeline and seven clinical trial programs
Exhibit 40: Seattle Genetics: ADC collaborations
Exhibit 41: Seattle Genetics: Key takeaways
Exhibit 42: Takeda: Business segmentation by revenue 2015
Exhibit 43: Takeda Pharmaceuticals: Geographical segmentation by revenue 2015
Exhibit 44: Takeda Pharmaceuticals: YoY growth and revenue generated from ADCETRIS (except US and Canada) 2013-2015 ($ millions)
Exhibit 45: Takeda Pharmaceuticals: Key takeaways

Enquiry Before Buy